Bromodomain-containing protein BRPF1 is a therapeutic target for liver cancer
Cheng et al. suggest that BRPF1 plays an oncogenic role in hepatocellular carcinoma (HCC), by controlling histone acetylation in the promoter regions of E2F2 and EZH2. Its high levels are correlated with poor survival in HCC patients, and targeting it might serve as a strategy for cancer treatment.
Guardado en:
Autores principales: | Carol Lai-Hung Cheng, Felice Hoi-Ching Tsang, Lai Wei, Mengnuo Chen, Don Wai-Ching Chin, Jialing Shen, Cheuk-Ting Law, Derek Lee, Carmen Chak-Lui Wong, Irene Oi-Lin Ng, Chun-Ming Wong |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/a00c4f2a8e644de8ab49c7c3c780d42a |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Genome-wide CRISPR/Cas9 library screening identified PHGDH as a critical driver for Sorafenib resistance in HCC
por: Lai Wei, et al.
Publicado: (2019) -
Hypoxia inducible factor HIF-1 promotes myeloid-derived suppressor cells accumulation through ENTPD2/CD39L1 in hepatocellular carcinoma
por: David Kung-Chun Chiu, et al.
Publicado: (2017) -
Transcriptional Networks Identify BRPF1 as a Potential Drug Target Based on Inflammatory Signature in Primary Lower-Grade Gliomas
por: Mingyang Xia, et al.
Publicado: (2021) -
Selective BET bromodomain inhibition as an antifungal therapeutic strategy
por: Flore Mietton, et al.
Publicado: (2017) -
A chemical toolbox for the study of bromodomains and epigenetic signaling
por: Qin Wu, et al.
Publicado: (2019)